Infusion-related reactions are common during or after the administration of liposomal drugs. For example, up to 10% of patients treated with Doxil
CPX-351 (United States: Vyxeos
Intensive monitoring for infusion-related reactions with CPX-351 administration had not previously been reported. This postmarketing, observational, single-arm, multicenter study (NCT03526926) was requested by the FDA to assess the nature, incidence, and severity of infusion-related reactions during an initial CPX-351 induction. All patients provided informed consent, and the study was approved by institutional review boards at each participating center. Prior to enrollment, the treating investigator decided to prescribe CPX-351 based on the approved US indications [[
Patients were observed for the first 6 days of the first CPX-351 induction cycle, from Day 1 of treatment until 1 day after the last infusion (Day 6), although patients may have received subsequent treatment at their physician's discretion. The incidence and severity of infusion-related reactions were evaluated during and for 90 minutes after the completion of each CPX-351 infusion. Treatment-emergent adverse events (TEAEs) were collected throughout the 6-day observation period and were graded according to the NCI-CTCAE version 4.03. TEAEs were followed until resolution, stabilization, or permanent sequelae were identified, or until the patient was lost to follow-up.
A total of 52 patients were enrolled in the study and received ≥1 CPX-351 induction. The median age was 64 years (range: 28, 78), with 67% of patients aged ≥60 years; 56% were male; 79% were White; and 23%, 46%, and 23% had Eastern Cooperative Oncology Group performance scores of 0, 1, and 2, respectively. Most patients had no history of allergies (63%), allergic asthma (98%), or autoimmune disorders (87%).
Most (94%) patients received all 3 infusions of the first CPX-351 induction (Table 1). Three patients discontinued the study. One patient developed a serious event of thromboembolism after receiving 2 CPX-351 doses and subsequently died. Another patient discontinued at their physician's discretion on Day 6 after receiving 2 CPX-351 doses due to a general decline with multiple adverse events that were not improving; the patient subsequently died on Day 10. Events for both patients were considered unrelated to CPX-351 by the investigators. The third patient discontinued on Day 2 after 1 CPX-351 dose due to tenuous health status and inability of the infusion center to collect study-mandated vital signs; this patient experienced grade 2 pyrexia (considered related to CPX-351) and grade 3 dyspnea (considered unrelated to CPX-351).
Table 1. Exposure to CPX-351.
CPX-351 ( Number of infusions Patients received ≥1 infusion 52 (100) Patients received 1 infusion 1 (2) Patients received 2 infusions 2 (4) Patients received 3 infusions 49 (94) Number of infusions/patient Mean (SD) 2.9 (0.3) Median (range) 3.0 (1, 3) Patients with dose interruptions during the treatment period 1 (2) Patients with dose interruptions on Day 1 of infusion 1 (2) Patients with dose interruptions on Day 3 of infusion 0 Patients with dose interruptions on Day 5 of infusion 0 Cumulative dose of daunorubicin, mg Mean (SD) 238.2 (53.8) Median (range) 247.5 (88, 339) Cumulative dose of cytarabine, mg Mean (SD) 542.4 (122.6) Median (range) 562.5 (204, 774)
1 SD: standard deviation.
One (2%) patient experienced infusion-related reactions during the study. This patient was a 68-year-old White male with AML evolving from prior myelodysplastic syndromes and no known history of asthma, allergies, or autoimmune diseases. He experienced grade 1 pyrexia on Day 2 (∼24 to 25 h after the first infusion on Day 1) and grade 2 dyspnea on Day 4 (∼21 h after the second infusion on Day 3). Both reactions were continuing at the end of the study (Day 6) but did not lead to dose change or interruption, treatment discontinuation, or withdrawal from the study.
In total, 39 (75%) patients experienced any grade TEAEs (including infusion-related reactions), and 13 (25%) patients experienced grade 3 or 4 TEAEs within the 6-day observation period (Table 2). Serious TEAEs were experienced by 6 (12%) patients and included grade 4 respiratory failure (n = 2 [4%]), grade 2 pyrexia, grade 3 dyspnea, grade 3 tumor lysis syndrome, grade 3 lung infection, grade 5 sepsis, grade 5 thromboembolism, and grade 5 cerebrovascular accident (n = 1 [2%] each). Of the serious TEAEs, only pyrexia and tumor lysis syndrome were considered related to CPX-351 by the investigator. Serious TEAEs of pyrexia, dyspnea, and tumor lysis syndrome resolved by Day 2, Day 3, and Day 12, respectively; although the lung infection was resolving, the patient died on Day 6 due to hemorrhagic stroke. Neither of the serious TEAEs of respiratory failure resolved; 1 of these patients also experienced a serious TEAE of sepsis that resulted in death. The serious TEAEs of thromboembolism and cerebrovascular accident also resulted in patient death. None of the 3 deaths due to serious TEAEs were considered related to CPX-351 by the investigator.
Table 2. Summary of TEAEs
CPX-351 ( Any TEAEb 39 (75) Constipation 9 (17) Fatigue 7 (13) Pneumonia 7 (13) Peripheral edema 6 (12) Headache 6 (12) Any grade 3 or 4 TEAEc 13 (25) Anemia 3 (6) Thrombocytopenia 2 (4) White blood cell count decreased 2 (4) Respiratory failure 2 (4) Any serious TEAE 6 (12) Respiratory failure 2 (4) Pyrexia 1 (2) Lung infection 1 (2) Sepsis 1 (2) Tumor lysis syndrome 1 (2) Cerebrovascular accident 1 (2) Thromboembolism 1 (2) Dyspnea 1 (2) Interruption due to TEAE 1 (2) Discontinuation due to TEAE 0 Death due to TEAE 3 (6)
- 2 TEAE: treatment-emergent adverse event.
- 3
a TEAEs reported during the 6-day study period from the start of the first CPX-351 infusion on Day 1 through 1 day after the last infusion (Day 6). - 4
b Subsequent list includes all individual TEAEs reported in >10% of patients. - 5
c Subsequent list includes all individual grade 3 or 4 TEAEs reported in >1 patient.
In this postmarketing, observational study in adults with newly diagnosed t-AML or AML-MRC, the frequency of infusion-related reactions with CPX-351 was low. No infusion-related reactions occurred on Day 1 of the first induction course of CPX-351. Among 52 patients, only 1 experienced infusion-related reactions, both of which were grade 1 to 2 and did not lead to study discontinuation. Similar rates of infusion-related reactions with CPX-351 treatment have been observed in other clinical studies; however, these studies were not designed to evaluate infusion-related reactions. In the pivotal phase 3 study, 2 of 153 (1%) patients in the CPX-351 arm experienced grade 2 infusion-related reactions, which was similar to the 7 + 3 comparator arm (2 of 151 [1%] patients with grade 1 or 2 reactions; data on file). In a phase 2 study of CPX-351 in newly diagnosed de novo or secondary AML, 1 of 85 (1%) patients had an infusion-related reaction (data on file). In a CPX-351 US early access program in patients with newly diagnosed high-risk/secondary AML, 1 of 52 (2%) patients experienced an infusion-related reaction (data on file).
Liposomal-based agents are known to induce infusion-related reactions, but the molecular basis of these reactions is not fully understood [[
The reported TEAEs and serious TEAEs in this study were consistent with the safety profile previously reported for CPX-351 in other clinical studies [[
Taken together, these data support the prior safety profile reported in the pivotal phase 3 study [[
The authors thank all the patients who participated in the study and their families, as well as the investigators, nurses, coordinators, and other research staff at each study site. Medical writing and editorial assistance were provided by Christina Sanders, PhD, of Cello Health Communications/SciFluent Communications, Inc., and were financially supported by Jazz Pharmaceuticals.
M.A.J. has received research funding from AbbVie and Jazz Pharmaceuticals. L.F. has served on speakers bureaus for Celgene, Jazz Pharmaceuticals, and Seattle Genetics. A.E. has received research grants from Jazz Pharmaceuticals and NewLink Genetics; is a global oncology advisory board member for Amgen; has served as an advisory board member for Genentech and Servier; and is a cofounder and scientific advisor for KinaRx. N.S.S. has served on speakers bureaus for AbbVie, Janssen, and Pharmacyclics; has served as an advisory board member for AbbVie, Janssen, Kite, Kyowa Kirin, and Pharmacyclics; and has served as a consultant for AbbVie. B.L.P has served as a consultant or advisor for Jazz Pharmaceuticals and Rafael Pharmaceuticals; and has received clinical research support from Genentech, Jazz Pharmaceuticals, Novartis, Pfizer, and Rafael Pharmaceuticals. K.S. has served on speakers bureaus for AbbVie, Alexion, Celgene, Incyte, Jazz Pharmaceuticals, Novartis, and Sanofi; and has received research support from Amphivena, Celgene, Jazz Pharmaceuticals, Onconova, Roche, and Sun Pharma. R.G. and S.F. are employees of and hold stock ownership/options in Jazz Pharmaceuticals. H.J.M. reports no conflict of interest.
All relevant data are provided within the manuscript and supporting files.
By Meagan A. Jacoby; Laura Finn; Ashkan Emadi; Nakhle S. Saba; Bayard L. Powell; Karen Seiter; Rosella Garcia; Stefan Faderl and Heather J. Male
Reported by Author; Author; Author; Author; Author; Author; Author; Author; Author